Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.

[1]  C. Robert,et al.  Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies. , 2015, Seminars in oncology.

[2]  A. Eggermont,et al.  Correction to Lancet Oncol 2015; 16: 522-30. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. , 2015, The Lancet. Oncology.

[3]  J. Kirkwood,et al.  Predictive importance of ulceration on the efficacy of adjuvant interferon-a (IFN): An individual patient data (IPD) meta-analysis of 15 randomized trials in more than 7,500 melanoma patients (pts). , 2014 .

[4]  A. Eggermont,et al.  Cutaneous melanoma , 2014, The Lancet.

[5]  R. Scolyer,et al.  The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients. , 2014, European journal of cancer.

[6]  R. Ádány,et al.  Correction: Integrative Genomics Identifies Gene Signature Associated with Melanoma Ulceration , 2013, PLoS ONE.

[7]  R. Ádány,et al.  Integrative Genomics Identifies Gene Signature Associated with Melanoma Ulceration , 2013, PloS one.

[8]  D. Schadendorf,et al.  Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  V. Lazar,et al.  Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity? , 2012, Current opinion in oncology.

[10]  D. Schadendorf,et al.  Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. , 2012, European journal of cancer.

[11]  I. V. D. van der Ploeg,et al.  Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Coit,et al.  Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Jeffrey E Gershenwald,et al.  Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Gordon.  Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis , 2010 .

[15]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Gordon.  Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial , 2009 .

[17]  A. Eggermont,et al.  Sentinel Node Tumor Burden According to the Rotterdam Criteria Is the Most Important Prognostic Factor for Survival in Melanoma Patients: A Multicenter Study in 388 Patients With Positive Sentinel Nodes , 2008, Annals of surgery.

[18]  A. Hauschild,et al.  EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. , 2008 .

[19]  R. Scolyer,et al.  Long-Term Protective Effect of Mature DC-LAMP+ Dendritic Cell Accumulation in Sentinel Lymph Nodes Containing Micrometastatic Melanoma , 2007, Clinical Cancer Research.

[20]  A. Eggermont,et al.  Gene expression profiling of primary cutaneous melanoma and clinical outcome. , 2006, Journal of the National Cancer Institute.

[21]  A. Eggermont,et al.  Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial , 2005, The Lancet.

[22]  D. Elder,et al.  Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas. , 2003, European journal of cancer.

[23]  M. Gore,et al.  Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. , 2003, Cancer treatment reviews.

[24]  L S Freedman,et al.  On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial. , 1976, Biometrics.